What if my tumor was completely removed and I feel better?

SSA looks at current function. Full resection is not disqualifying if you still have persistent motor loss, cognitive deficits, hormonal dependence, vision loss, or hearing loss meeting A or B.

Can cognitive symptoms alone qualify me under 11.05?

Paragraph B requires marked physical AND marked mental. Pure cognitive impairment without physical limitation routes through 12.02 neurocognitive disorder listing instead.

Does vestibular schwannoma qualify because of hearing loss?

Not under 11.05 alone. Isolated hearing loss routes to 2.10 or 2.11. 11.05 requires motor or balance loss under Paragraph A, or marked physical plus mental under B.

How do I get compassionate allowance fast track for a benign tumor?

Most benign tumors are not on the CAL list. Bilateral vestibular schwannomas from NF2 qualify via the NF2 CAL listing. TERI or dire need flags can speed non-CAL cases.

Listing 11.05 Benign Brain Tumors in 2026: The Full Blueprint on Paragraph A Motor Disorganization and Paragraph B Marked Physical Plus Marked Mental Limitation for Meningioma, Vestibular Schwannoma, Pituitary Adenoma, Craniopharyngioma, and Other Non-Malignant Brain Tumors

Q: Is a benign brain tumor automatically approved for SSDI?

No. You must meet Paragraph A extreme motor limitation or Paragraph B marked physical plus marked mental limitation. Benign diagnosis alone does not qualify.

Q: What if my tumor was treated 10 years ago and I recently got worse?

Late effects of tumor and radiation qualify. SSA evaluates you at the date you file, not the date of original diagnosis. Radiation cognitive decline can appear 5 to 15 years post treatment.

Q: Do I need a lawyer to file for benefits under 11.05?

You can file without one. At reconsideration or hearing, a representative often helps because DDS commonly misreads benign versus malignant or marked versus moderate. Fees are capped at 25 percent of back pay up to 9,200 dollars in 2026.

By Anthony Albert, Benefits Research Director at Disability Exchange. Updated for 2026 claims. This piece continues our Section 11 neurological listings deep dive. If you have not read our companion pieces on 11.04 stroke, 11.18 TBI, and 11.17 neurodegenerative disorders, start with those first because 11.05 borrows the same 11.00D and 11.00G machinery.

Here is the quick version. Listing 11.05 is SSA's Blue Book pathway for benign (non-cancerous) brain tumors. It has two paragraphs. Paragraph A is about extreme motor loss. Paragraph B is about marked physical plus marked mental limitation. You only need to meet one of them, and both use the exact same 11.00D and 11.00G rules used in the stroke, MS, and Parkinson listings you already know.

Here is the piece most people miss. If your tumor is malignant, you do not use 11.05, you use 13.13 (nervous system cancer). If your tumor causes only cognitive problems and no physical loss, 11.05 can still work under Paragraph B, but you must document marked physical limitation too. If you have vision or hearing loss from the tumor pressing on cranial nerves, we route you to 2.02, 2.03, or 2.10 as needed. All of this matters because the wrong route gets you a technical denial before medical review even starts.

You get a paycheck for benefits if you meet Paragraph A or Paragraph B. You keep it after meeting the medical improvement not expected rule at Continuing Disability Review. The whole thing is winnable but the file has to be built right. Let's walk through it.

Not sure if your brain tumor claim meets 11.05?
Get a free case review before you file, appeal, or hire anyone.
See If You Qualify

What the 2026 listing actually says (verbatim)

Here is the text of Listing 11.05 as it reads in the 2026 Blue Book. Memorize it. Every ALJ decision on this listing quotes it.

11.05 Benign brain tumors, characterized by A or B:

A. Disorganization of motor function in two extremities (see 11.00D1), resulting in an extreme limitation (see 11.00D2) in the ability to stand up from a seated position, balance while standing or walking, or use the upper extremities.

B. Marked limitation (see 11.00G2) in physical functioning (see 11.00G3a), and in one of the following areas of mental functioning:

1. Understanding, remembering, or applying information (see 11.00G3b(i)); or
2. Interacting with others (see 11.00G3b(ii)); or
3. Concentrating, persisting, or maintaining pace (see 11.00G3b(iii)); or
4. Adapting or managing oneself (see 11.00G3b(iv)).

Two paragraphs. Both point outward to 11.00. That's where all the actual definitions live.

11.00D1: What "disorganization of motor function" means

11.00D1 is the same rule you saw in the 11.04 stroke, 11.06 Parkinson's, 11.07 cerebral palsy, 11.09 MS, and 11.17 neurodegenerative articles. The rule reads: disorganization of motor function means interference, due to your neurological disorder, with movement of two extremities. Interference includes weakness, tremor, spasticity, chorea, athetosis, dystonia, ataxia, and sensory loss that affects balance or coordination.

Two extremities. Not one. Two. That is the trip wire that kills a lot of 11.05 cases. If your meningioma sits on the left motor strip and you have a right-side hemiparesis with the left side normal, that is only one side involved and Paragraph A is not going to fit unless you can show both a leg and an arm on the same side count as two extremities. SSA does count same-side arm plus leg as two extremities for 11.00D1 purposes. That's the escape hatch you need.

The other escape hatch is when the tumor causes a broader syndrome. A craniopharyngioma pressing on the optic chiasm plus the third ventricle can cause a diffuse gait disorder that affects both legs. A vestibular schwannoma removed by translabyrinthine approach can leave you with severe vestibular loss that makes both lower extremities functionally unusable for standing and walking, even though motor strength is normal. SSA treats loss of balance from a peripheral cause as motor disorganization when it meets the extreme limitation test.

11.00D2: What "extreme limitation" means for Paragraph A

11.00D2 gives you three endpoints. Extreme limitation is the inability to:

Stand up from a seated position without help from another person or a device such as a walker, canes, or crutches, and
Maintain balance in a standing position and while walking, or
Use the upper extremities to independently initiate, sustain, and complete work-related activities involving fine and gross movements.

For 11.05 you only need to meet one of these three endpoints. If you can't stand up without a walker after a suboccipital craniotomy for a tumor, you meet the first. If your gait is a wide-based ataxia and you fall multiple times a week without a device even indoors, you meet the second. If you have bilateral hand tremor from a tumor and can't button a shirt or type at any reliable pace, you meet the third.

11.00G2, G3a, and G3b: Paragraph B in detail

Paragraph B is where most 11.05 cases actually live. Tumors more often cause a mix of mild motor issues plus significant cognitive impairment. That fits B better than A.

11.00G2 "marked": Your functioning independently, appropriately, effectively, and on a sustained basis is seriously limited. Not extreme. Just seriously limited. Think of it as the middle of a five-point scale: none, mild, moderate, marked, extreme.

11.00G3a physical functioning: Balance, standing, walking, using the upper extremities, and any physical task an employer would require. You need marked in physical.

11.00G3b mental areas (pick one):

Understanding, remembering, or applying information. This picks up memory loss from a temporal lobe meningioma or from cranial radiation.
Interacting with others. Frontal lobe tumors and their aftermath change personality, social filtering, disinhibition.
Concentrating, persisting, or maintaining pace. Slowed processing speed from tumor plus surgery plus radiation. Very common.
Adapting or managing oneself. Executive dysfunction, poor self-monitoring, inability to plan or shift tasks.

You need marked in one of those four. Plus marked in physical. Two markeds, one physical and one mental.

The tumors you'll see in these files

Meningioma

The most common benign brain tumor. Grade I is truly benign. Grade II atypical meningioma and Grade III anaplastic get routed to 13.13. Grade I still causes major functional loss because location trumps grade. A convexity meningioma over the motor strip, a parasagittal meningioma near the sensorimotor cortex, a sphenoid wing meningioma affecting the cavernous sinus and cranial nerves, a foramen magnum meningioma at the craniocervical junction. Each location destroys a different function set.

Treatment picture in 2026: gross total resection (Simpson Grade I-II) is the gold standard when safely possible. Stereotactic radiosurgery (Gamma Knife, CyberKnife) for lesions under 3 cm at the skull base. Fractionated radiotherapy for larger residual tumors. Watchful waiting with serial MRI for asymptomatic small lesions. Bevacizumab off-label for radiation necrosis. New in 2023-2025: prospective trials of the somatostatin analog pasireotide for progressive meningioma expressing SSTR2. LOXO-338 and other AKT inhibitors in NF2-mutant meningioma. Vismodegib for hedgehog pathway meningiomas.

Vestibular schwannoma (acoustic neuroma)

Arises from the vestibular portion of cranial nerve VIII in the internal auditory canal. Sporadic tumors are unilateral. Bilateral tumors mean NF2 (neurofibromatosis type 2) and route through Compassionate Allowance in some cases. Symptoms: unilateral sensorineural hearing loss, tinnitus, imbalance, vertigo. Large tumors compress the brainstem and cerebellum causing ataxia, hydrocephalus, facial nerve involvement.

2026 treatment picture: microsurgery via retrosigmoid, translabyrinthine, or middle fossa approaches depending on tumor size and residual hearing. Stereotactic radiosurgery for tumors under 2.5 to 3 cm. Bevacizumab for NF2-related schwannomas causing progressive hearing loss. Brigatinib for NF2 (based on 2024 INTUITT-NF2 basket trial data). Cochlear implants after treatment when auditory nerve is preserved. Auditory brainstem implants (ABI) when the nerve is sacrificed.

For 11.05 purposes: post-surgical vestibular loss producing extreme balance limitation meets Paragraph A. Facial nerve palsy plus bilateral vestibular loss (NF2) is a strong case.

Pituitary adenoma

Non-functioning macroadenomas cause bitemporal hemianopsia (route the vision loss through 2.03) plus panhypopituitarism. Functioning adenomas by hormone: prolactinoma (dopamine agonists first line, cabergoline standard), somatotropinoma causing acromegaly (surgical, then somatostatin analogs octreotide LAR, lanreotide, pasireotide LAR; GH receptor antagonist pegvisomant), corticotropinoma causing Cushing disease (surgery, radiotherapy, mifepristone, mitotane, ketoconazole, osilodrostat, pasireotide, and adrenalectomy of last resort), thyrotropinoma (rare, TSH-secreting), gonadotroph (usually silent).

For 11.05 the surgical route matters. Transsphenoidal endoscopic surgery leaves most patients with panhypopituitarism requiring lifelong hydrocortisone, levothyroxine, testosterone or estrogen, sometimes desmopressin for diabetes insipidus, and sometimes growth hormone. Chronic fatigue from hormonal replacement issues plus vision loss plus cognitive issues from cavernous sinus involvement can build a Paragraph B case.

Craniopharyngioma

Adamantinomatous or papillary. Sit at or near the pituitary stalk. Both types are grade I but behave badly because of location. Recurrence rates are high. Adult craniopharyngiomas often present with vision loss, hypothalamic obesity, hypopituitarism, cognitive decline, and behavioral changes. 2026 targeted treatment: BRAF/MEK inhibitors (dabrafenib plus trametinib) for BRAF V600E mutant papillary craniopharyngioma per the ATTLE trial. Intracystic bleomycin or interferon for cystic recurrences. Stereotactic radiotherapy for residuals. Hypothalamic obesity treated with GLP-1 agonists (semaglutide, tirzepatide) and setmelanotide (Imcivree, FDA-approved 2020 for POMC and LEPR deficiency, off-label for hypothalamic obesity).

Hemangioblastoma

Vascular tumor of the cerebellum or spinal cord. Often part of von Hippel-Lindau disease. Watch for VHL-associated pheochromocytoma, renal cell carcinoma, retinal hemangioblastoma, pancreatic cysts. 2021 approval of belzutifan (Welireg), a HIF-2 alpha inhibitor, changed VHL treatment. Cerebellar hemangioblastomas cause severe truncal ataxia and dysmetria which fit Paragraph A cleanly.

Colloid cyst of the third ventricle

Benign but can be deadly. Sudden obstruction of the foramen of Monro causes acute hydrocephalus, coma, sudden death. Treated by endoscopic resection or open transcallosal approach. Survivors often have memory loss (from fornix injury) and executive dysfunction. Strong Paragraph B fit.

Choroid plexus papilloma

Rare in adults, more common in kids. Grade I but causes hydrocephalus, ventriculomegaly, and cognitive changes.

The diagnostic file SSA needs to see

MRI brain with and without gadolinium contrast. T1, T2, FLAIR, DWI, and post-contrast T1 sequences. Read by a neuroradiologist. Tumor location, size, edema, midline shift, hydrocephalus documented.
Pathology report if resected. Grade, mitotic index, Ki-67 proliferation index, molecular markers (NF2 status for meningioma, BRAF V600E for craniopharyngioma, TERT promoter mutation).
Operative report from neurosurgeon. Approach, extent of resection (Simpson grade for meningioma), complications, cranial nerve status at end of case.
Neurology followup notes.
Neuro-ophthalmology exam with visual fields (Humphrey 30-2) and OCT of the retinal nerve fiber layer if visual pathway involved.
Audiogram and vestibular testing (VNG, VEMP, rotary chair) for schwannomas.
Endocrinology workup for pituitary and hypothalamic tumors. Morning cortisol, ACTH, IGF-1, TSH, free T4, prolactin, LH, FSH, testosterone or estradiol, DHEA-S, sodium (for DI or SIADH).
Neuropsychological testing. Full battery: WAIS-IV, WMS-IV, Trail Making A and B, Stroop, Wisconsin Card Sort, Boston Naming, Rey Complex Figure, Grooved Pegboard, Beck Depression and Anxiety Inventories.
Physical therapy notes for gait analysis and Berg Balance Scale, Tinetti, Timed Up and Go.
Occupational therapy notes for fine motor tasks and ADL scoring (Barthel or FIM).

Worked Example 1: Meningioma with Extreme Motor Limitation (Paragraph A)

Claimant: Miriam, 54, Cambridge, Massachusetts. Prior work as an accountant, past relevant work skilled sedentary.

Diagnosis: Left parasagittal meningioma at the sensorimotor cortex, WHO Grade I, gross total resection at Brigham and Women's July 2024 (Simpson Grade II). Postoperative right hemiparesis due to venous infarct in the superior sagittal sinus territory. Radiation not needed given complete resection.

Postop course: Right upper extremity 3/5 strength distal, 4/5 proximal, right lower extremity 3/5 hip flexors, 2/5 dorsiflexion. Left side normal. Uses a hemi-walker at home and a rollator outside. Cannot stand up from a chair without pushing off with the left arm and takes multiple attempts. Falls twice a month even indoors. On aspirin plus atorvastatin. Chronic fatigue.

SSA angle: Right leg plus right arm count as two extremities under 11.00D1 (same-side counts). She meets 11.00D1. Extreme limitation in standing up from a seated position under 11.00D2 (needs left arm push plus multiple attempts to rise) plus extreme limitation in balance (falls without device). Meets Paragraph A on two of the three endpoints, only needs one.

Result: Allowed at initial. DDS relied on treating neurosurgeon's medical source statement plus physiatry gait analysis (Berg 24/56) plus OT ADL scoring (Barthel 55 of 100). Allowed with medical improvement not expected review cycle at 7 years.

Worked Example 2: Craniopharyngioma with Paragraph B (marked physical plus marked mental)

Claimant: Andres, 47, Miami, Florida. Prior work as a warehouse supervisor.

Diagnosis: Adamantinomatous craniopharyngioma, BRAF V600E negative, transsphenoidal partial resection at Miami Cancer Institute March 2024 followed by proton beam radiotherapy 54 Gy in 30 fractions completed August 2024. Postoperative panhypopituitarism, diabetes insipidus, hypothalamic obesity (BMI 42, up from 31 preop), bitemporal hemianopsia residual on visual field testing, cognitive slowing.

Postop course: Hydrocortisone 30 mg AM and 10 mg PM, levothyroxine 137 mcg, testosterone cypionate 200 mg IM q2 weeks, desmopressin 0.2 mg BID, semaglutide 2.4 mg weekly for hypothalamic obesity with only modest response, growth hormone deferred. Neuropsych at 12 months post-radiation: FSIQ 91 (average), processing speed index 74 (borderline), working memory index 79, Trails B 3rd percentile, Wisconsin Card Sort 4 categories with 42 perseverative errors, D-KEFS letter fluency 5th percentile. Gait normal but severely deconditioned, 6 minute walk distance 220 meters (roughly 30% predicted).

SSA angle: Marked physical under 11.00G3a (severe fatigue, 220 meter walk distance, morning cortisol dependence with adrenal crisis risk, cannot sustain 8 hour physical activity). Marked mental in concentrating, persisting, or maintaining pace under 11.00G3b(iii) based on processing speed index 74, Trails B 3rd percentile, and Wisconsin Card Sort perseverative pattern. Also could argue marked in understanding, remembering, or applying information under G3b(i) via working memory index 79 and delayed memory issues on WMS-IV.

Result: Allowed at reconsideration after initial denial. DDS on the initial round hung on "cognitive scores are borderline not marked" and missed that borderline range plus tanking on tests of sustained effort equals marked functionally. Reconsideration reviewer used the neuropsychologist's medical source statement plus endocrinology's letter documenting adrenal insufficiency plus PT's 6MWT record to reverse the denial.

Common file-building mistakes on 11.05 claims

Mistake 1: Treating this as a cancer listing

11.05 is for benign tumors only. Grade II atypical meningioma routes to 13.13. Grade III anaplastic meningioma routes to 13.13. Any glioma of any grade routes to 13.13. If your surgeon says benign in the note but the pathology report says atypical, believe the pathology report and file under 13.13. Cross-check before you file.

Mistake 2: Only citing one side of a hemiparesis

Same-side arm plus same-side leg counts as two extremities under 11.00D1. Don't let the DDS reviewer say "only one side involved" without pushing back. Cite the exact language of 11.00D1.

Mistake 3: Missing the vestibular and cranial nerve data

Vestibular schwannoma cases live or die on VNG, VEMP, rotary chair, and audiogram data. If your file has an MRI showing a 3 cm CPA tumor and a subjective complaint of imbalance but no vestibular battery, the reviewer has nothing to hang extreme limitation on. Get the testing.

Mistake 4: Skipping neuropsych after radiation

Cranial radiation causes cognitive decline. Not maybe. Definitely. Neuropsych at 6, 12, and 24 months post-radiation is the norm at NCI-designated centers. If your treating team hasn't ordered it, ask. Without neuropsych scores you cannot prove marked mental for Paragraph B.

Mistake 5: Not documenting cortisol dependence

Panhypopituitarism after tumor treatment means adrenal insufficiency. Adrenal crisis kills people. That is a functional limitation SSA has to weigh. Endocrinology note documenting cortisol replacement, stress dose instructions, MedicAlert bracelet, and any crisis events (ED visits, IV hydrocortisone) belongs in the file.

Mistake 6: Ignoring vision field loss

Chiasmal compression from pituitary tumors or craniopharyngiomas produces bitemporal hemianopsia. Post-treatment field loss often persists. Cross-route through 2.03 loss of visual efficiency in addition to 11.05. Or add the vision loss as a supporting factor in the physical functioning marked argument under 11.00G3a.

How 11.05 interacts with SGA and 2026 payments

Substantial Gainful Activity in 2026 is $1,620 per month non-blind and $2,700 per month statutorily blind. If a claimant with a pituitary tumor plus bitemporal hemianopsia has vision loss severe enough to meet the statutory blindness definition (best-corrected central visual acuity of 20/200 or less in the better eye, or a visual field with a widest diameter no greater than 20 degrees), they use the higher SGA figure. Most 11.05 claimants use the non-blind threshold.

Trial Work Period threshold for 2026 is $1,110 per month gross. Extended Period of Eligibility runs 36 months after TWP completes. Impairment-related work expenses (hearing aids, cochlear implant batteries, transportation for chemo, cognitive rehab copays, hormone medications above what most workers pay) get subtracted from gross earnings before SGA is calculated.

How to Build a Winning 11.05 File in 8 Steps

Confirm the tumor is benign. Pull the pathology report. WHO grade must be I (or II depending on tumor type). Verify at least twice, because the difference between benign and malignant sends you to a different listing.
Map the tumor location to functional deficits. Convexity meningioma over the motor strip suggests Paragraph A. Sellar or suprasellar craniopharyngioma suggests Paragraph B. Cerebellar hemangioblastoma suggests Paragraph A (ataxia).
Order the missing tests. Ask the treating team for neuropsych, vestibular battery, endocrine panels, visual fields, and gait analysis as appropriate. Six weeks of prep beats a technical denial.
Get the medical source statement. HA-1152 or attorney template. Have neurosurgery, neurology, endocrinology, and neuropsychology all sign off with functional statements.
File the application. Use SSA's Compassionate Allowance list if applicable. Bilateral vestibular schwannomas from NF2 are on the CAL list. Adult early-onset dementia from tumor sequelae is not, but you can request TERI or dire need flagging.
Track the DDS request for records. Follow up with treating providers to make sure records are sent within the DDS deadline (usually 10 days).
Prepare for the CE if ordered. Consultative exams are shallow. Ask your rep to accompany you and to submit prior medical evidence in advance.
Appeal early denials with new evidence. Reconsideration is where craniopharyngioma files often win because that's when neuropsych scores and endocrine records finally arrive. Don't give up on initial denial.

Frequently asked questions about Listing 11.05

Is a benign brain tumor automatically approved for SSDI?

No. Benign is not automatic. You have to meet Paragraph A or Paragraph B of Listing 11.05. That means proving functional loss that reaches extreme or marked, not just showing that a tumor exists.

What if my tumor was completely removed and I'm doing better?

SSA looks at your current functional status. If you've recovered fully and can work at SGA level, you don't meet 11.05. If you have persistent motor loss, cognitive deficits, hormonal dependence, vision loss, or hearing loss that limits you enough to meet A or B, you still qualify. Full resection is not disqualifying.

Can I qualify if I only have cognitive problems and no physical issues?

Paragraph B requires marked physical plus marked mental. If you have zero physical limitation and only cognitive deficits, you don't meet 11.05 directly. You'd route through 12.02 (neurocognitive disorder) instead. But if you have any marked physical limitation (fatigue from panhypopituitarism, deconditioning after long treatment, gait mildly abnormal), you can build a 11.05 Paragraph B case with the mental limitation as the anchor.

Does vestibular schwannoma automatically qualify because of the hearing loss?

Not under 11.05. Isolated hearing loss routes to 2.10 (hearing loss without cochlear implant) or 2.11 (with cochlear implant, one year to auto-cease). To qualify under 11.05, the tumor has to cause motor or balance loss meeting Paragraph A, or marked physical plus marked mental for Paragraph B.

How do I get on the Compassionate Allowance fast track for a benign brain tumor?

Most benign tumors are not on the CAL list. Exceptions include bilateral vestibular schwannomas from NF2 (via the NF2 CAL listing). For non-CAL cases, ask the field office to flag your case as TERI (terminal) if the tumor is inoperable and life-limiting, or dire need if you're facing imminent loss of housing or medical care. Neither is guaranteed, but flagging can speed up review.

What if I had my tumor treated 10 years ago but recently got worse?

Late effects of tumor and radiation are common. Radiation-induced cognitive decline can appear 5 to 15 years post-treatment. Radiation necrosis, secondary meningioma, hypopituitarism worsening, cognitive decline from methotrexate or vincristine (rare in benign but possible). SSA evaluates you as of the date you file, not the date of original diagnosis. Recent functional decline builds a fresh claim.

Do I need a lawyer to file for benefits under 11.05?

You can file without one. Most people do. But the neuroscience is dense and the DDS often misreads the difference between benign and malignant, or between marked and moderate. If you're at reconsideration or hearing, a representative is worth considering. Fees are capped at 25% of back pay up to $9,200 in 2026 (raised from $7,200 in November 2024).

Ready to start your 11.05 claim?
Free eligibility check in under two minutes. No obligation.
See If You Qualify

Related deep dives on this site

Disclosure: This is a privately owned website and is not affiliated with or endorsed by the Social Security Administration (SSA). Disability Exchange is an independent information resource. Information here is educational and not legal advice.